NRG-GY018 at ASCO 2026: Pembrolizumab Plus Chemotherapy Sustains Overall Survival Benefit in Advanced Endometrial Cancer
oncodaily - The NRG-GY018 trial returned to the ASCO 2026 stage with the question that matters more than any progression endpoint: do patients actually live longer? Presented by Ramez N. Eskander, MD […]
AI Summary: Updated results from the NRG‑GY018 trial show adding pembrolizumab to chemotherapy sustains an overall survival benefit in advanced endometrial cancer. The follow‑up confirms the durability of immunotherapy’s impact and supports integrating checkpoint inhibitors into standard regimens for eligible patients, potentially changing practice for a cancer type that’s long hungered for better systemic options.
Related Stories
Zanidatamab improves PFS over trastuzumab in HER2 GEA / 6 days
MAGE‑A4/A8 TCR bispecific T‑cell engager shows activity in solid tumors / 6 days
Teclistamab outperforms standard regimens in earlier-line relapsed myeloma / 8 days
Common asthma drug may overcome immunotherapy resistance in cancers / 17 days
Retifanlimab plus chemotherapy extends survival in advanced squamous anal cancer / 20 days
Zoldonrasib shows durable responses in KRAS G12D lung cancer / 6 wks
James P. Allison wins AACR lifetime achievement award / 1 month
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Olfaction, Animal Health, Pediatric Oncology, Government Policy and look for the RSS link.
StackHealth Time Machine